Atea Pharmaceuticals Reports Its Cash, Cash Equivalents And Marketable Securities Balance Of $454.7M At December 31, 2024 And A Cash Runway Anticipated Into 2028
Benzinga Newsdesk 1 year ago
BiotechNewsGuidanceHealth CareGeneral
Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in
- Global Phase 3 HCV Program Expected to Initiate in 1Q 2025
- Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales
- The Regimen, if Approved, Should Play an Important Role in Efforts to Reduce the Continuing High Disease Burden of HCV